Keller Roberta L, Moore Phillip, Teitel David, Hawgood Samuel, McQuitty John, Fineman Jeffrey R
Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Pediatr Crit Care Med. 2006 Nov;7(6):589-94. doi: 10.1097/01.PCC.0000244401.53189.CB.
We describe four cases of chronic pulmonary hypertension in infants and children with chronic lung disease and pulmonary hypoplasia due to severe congenital diaphragmatic hernia (CDH) or congenital cystic adenomatoid malformation (CCAM). We report data from cardiac catheterization under various conditions: baseline respiratory support and room air, hyperoxic and inhaled nitric oxide challenge. We further report cardiac catheterization measures after chronic pulmonary vasodilator therapy with sildenafil alone or a combination of sildenafil and inhaled nitric oxide (three patients).
Case series.
Tertiary academic center.
Infants and children ages 0-11 yrs with CDH (n = 3) or CCAM (n = 1) with evidence of chronic pulmonary hypertension by echocardiogram and cor pulmonale (n = 3).
Catheterization and pulmonary vasodilator therapy.
Pulmonary vascular resistance, pulmonary arterial pressure, and changes in these measures were assessed. A 20% change in pulmonary vascular resistance was considered a clinically significant response. Ten catheterizations were performed in four patients. All patients had elevated pulmonary vascular resistance and pulmonary arterial pressures at initial catheterizations and significant vasodilation during inhaled nitric oxide.
Chronic lung disease following pulmonary hypoplasia from CDH and CCAM is associated with abnormal pulmonary vascular tone in infants and children with evidence of chronic pulmonary hypertension. Chronic pulmonary vasodilator therapy may improve pulmonary vascular function and enhance lung growth in infants and children who are treated during their period of potential for rapid lung growth.
我们描述了4例因严重先天性膈疝(CDH)或先天性囊性腺瘤样畸形(CCAM)导致慢性肺部疾病和肺发育不全的婴幼儿慢性肺动脉高压病例。我们报告了在各种情况下的心导管检查数据:基线呼吸支持和室内空气、高氧和吸入一氧化氮激发试验。我们还报告了单独使用西地那非或西地那非与吸入一氧化氮联合进行慢性肺血管扩张治疗后的心脏导管检查结果(3例患者)。
病例系列。
三级学术中心。
年龄0至11岁的患有CDH(n = 3)或CCAM(n = 1)的婴幼儿,经超声心动图证实有慢性肺动脉高压且有肺心病(n = 3)。
导管插入术和肺血管扩张治疗。
评估肺血管阻力、肺动脉压力以及这些指标的变化。肺血管阻力变化20%被认为是具有临床意义的反应。4例患者共进行了10次导管插入术。所有患者在初次导管插入时肺血管阻力和肺动脉压力均升高,吸入一氧化氮期间有显著的血管扩张。
CDH和CCAM导致肺发育不全后的慢性肺部疾病与有慢性肺动脉高压证据的婴幼儿肺血管张力异常有关。慢性肺血管扩张治疗可能改善肺血管功能,并促进处于肺快速生长潜力期的婴幼儿的肺生长。